Meeting NewsVideo

VIDEO: Diabetes drug ‘very logical’ choice for combination therapy in NASH

VIENNA — In this exclusive video from the 2019 International Liver Congress, Rob Myers, MD, vice president of the liver diseases therapeutic area at Gilead, discusses a collaboration between Gilead and Novo Nordisk.

“We did announce intent to collaborate with Novo Nordisk on a clinical collaboration in NASH,” Myers told Healio Gastroenterology and Liver Disease. “Our plan here is to combine the expertise in diabetes and metabolic disease with our expertise in liver diseases and the development of combination treatments for liver diseases.”

The intention, according to Myers, is to conduct a proof-of-concept study that will combine Ozempic (semaglutide; Novo Nordisk), a GLP-1 agonist, with both cilofexor (Gilead) and firsocostat (Gilead) in patients with NASH.

“We’re very excited about this collaboration because we believe that NASH is a complex disease and we will need to combine medications that have complementary mechanisms of action to achieve the desired benefits in our patients with NASH and advanced fibrosis,” he said.

Disclosure: Myers is an employee of Gilead.

VIENNA — In this exclusive video from the 2019 International Liver Congress, Rob Myers, MD, vice president of the liver diseases therapeutic area at Gilead, discusses a collaboration between Gilead and Novo Nordisk.

“We did announce intent to collaborate with Novo Nordisk on a clinical collaboration in NASH,” Myers told Healio Gastroenterology and Liver Disease. “Our plan here is to combine the expertise in diabetes and metabolic disease with our expertise in liver diseases and the development of combination treatments for liver diseases.”

The intention, according to Myers, is to conduct a proof-of-concept study that will combine Ozempic (semaglutide; Novo Nordisk), a GLP-1 agonist, with both cilofexor (Gilead) and firsocostat (Gilead) in patients with NASH.

“We’re very excited about this collaboration because we believe that NASH is a complex disease and we will need to combine medications that have complementary mechanisms of action to achieve the desired benefits in our patients with NASH and advanced fibrosis,” he said.

Disclosure: Myers is an employee of Gilead.

    See more from International Liver Congress